Gil Roth

Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.

Politics, drug prices, tax reform, regulatory uncertainty leave CDMOs/CMOs guessing about pharma’s future.

The outlook for the CMO and CDMO industry may be affected by ever-changing politics.